Table 1 Baseline clinical characteristics and post-anti-PD-1 outcomes
Patient no. | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
Age (years) | 54 | 40 | 41 | 38 | 35 |
Sex | M | F | F | M | F |
ECOG performance status | 0 | 2 | 1 | 0 | 2 |
Diagnosis/stage | DLBCL/IV | DLBCL/IV | DLBCL/III | DLBCL/IV | DLBCL/III |
Disease status1 | Relapsed | Primary refractory | Primary refractory | Relapsed | Primary refractory |
Target lesion | Bilateral parotid nodule | Bone marrow, spleen, lymph nodes (9 regions) | Lymph nodes (2 regions) | Bone, lymph node | Lymph node |
Prior system regimens | RCHOP × 5, RDICE × 3, RGEMOX × 9, RMTX × 2, RAD × 6, BEACOPP × 2 | RCHOP × 8, DHAP × 4, CART19 | CHOPE × 4, RDICE × 6, RDHAP × 4, IR × 2 | RCHOPE × 2, ABVD × 3, DICE × 4, ESHAP × 7, BEAM × 2, R2 × 6 | REPOCH × 8, GEMOX × 2 |
Prior RT | Yes | No | No | No | No |
Prior ASCT | Yes | No | No | No | No |
Prior CD19/CD20 CAR-T | Yes | Yes | Yes | Yes | Yes |
Best response | CR | CR | PR | CR | PD |
Final response | PD | PD | PD | PD | PD |
PFS (months) | 6 | 6 | 5 | 3 | 3 |
Percentage of PD-L1+ expression2 | 0 | 0 | 30% | 70% | 0 |
Percentage of PD-L1+ expression3 | 30% | 0 | 40% | 80% | 0 |
Percentage of PD-1+ expression2 | 0 | 0 | 20% | 0 | 0 |
Percentage of PD-1+ expression3 | 80% | 5% | 60% | 60% | 0 |
Anti-PD-1 therapy | |||||
Antibody type (treatment cycle) | Sintilimab (12) | Camrelizumab (1) | Sintilimab (5) | Camrelizumab (24) | Sintilimab (2) |
Best response | CR | PD | PR | CR | PD |
Final response | PD | PD | PD | CR | PD |
PFS (months) | 10.1 | 0.63 | 3.3 | 21.8 | 1 |
OS (months) | NE | 16.2 | NE | NE | 15.6 |
TrAE (grade) | Increased transaminase (1) | None | Fever (2), leukocytopenia (2) | Fever (1), rash (1) | None |